DURHAM, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at ...
For many years, 2 axioms have ruled our thoughts and discussions of coronary atherosclerosis. The first axiom was that patients were at risk for acute coronary syndromes (ACS) if their coronary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results